Despite the impact of the COVID-19 pandemic on industry events and our ability to interact in person with one another as a global scientific community through 2021, the last 12 months have still provided invaluable opportunities for Quotient Sciences to make a positive difference for our customers, their drug development programs and our shared ambition to accelerate the availability of new medicines for patients.
At Quotient, we take great pride in the science and innovation that we help bring to our customers and the pharmaceutical industry at large. We are firm believers that sharing knowledge and experience with the wider pharmaceutical and biotech communities will help accelerate the development of new medicines and technologies around the world.
In 2021, Quotient Sciences’ scientific thought leaders were again hard at work, collaborating to publish peer-reviewed publications through a wide variety of media outlets. Accomplishments this year included the presentation of 16 posters, the publication of 8 manuscripts, and the delivery of 7 podium talks at industry events across the globe. My thanks go to all my colleagues involved in the preparation and delivery of this content and more importantly the fantastic support from our customers.
Throughout 2021, we have also made continued investments to increase our drug substance and drug product capabilities to better support customer needs. In February 2021, Quotient Sciences acquired and rebranded Arcinova, an Alnwick, UK-based CDMO, adding Drug Substance Synthesis and Manufacturing, Bioanalysis, and Radiosynthesis capabilities to Quotient’s existing drug product and clinical testing toolkit. These new capabilities were showcased in publications at ISSX, the European Bioanalysis Forum, EASL, and in the Bioanalysis Journal. Quotient later announced a multi-million pound project to expand drug substance synthesis in Alnwick to further improve our end-to-end offering of capabilities for customers across the entire drug development pathway, from candidate selection through commercial product release.
Each day, we are proud to work with our customers to design and deliver integrated programs towards a common goal of accelerating the availability of new medicines for patients – and as a result, improving global health.
Details and links to some of the key papers and posters from this past year are provided below.
Please contact us if you would like any further information on any of our publications or new capabilities.
Kind regards,
Peter Scholes, CSO at Quotient Sciences
Scientific Posters
- "Pharmaceutical and clinical performance comparisons of modified release multiparticulates and matrix tablet formulations” from AAPS PharmSci 360
Access here - "Development of modified release matrix tablet using solid lipid Compritol® 888" from AAPS PharmSci 360
Access here - "Influence of drug loading and fillers on drug release from HPMC matrix tablets" from AAPS PharmSci 360
Access here - "Development and application of a PBPK model to assess the potential of biorelevant in vitro dissolution methods to predict the impact of formulation changes on oral bioavailability of GB001." from AAPS PharmSci 360
Access here - "Taste Assessment Study of Belumosudil to Inform an Integrated Paediatric Formulation Development Program" from EuPFI conference
Access here - "Development of a Novel Paediatric Belumosudil Oral Suspension" from EuPFI conference
Access here - "Assessment of Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of R941552 (R552) in Healthy Subjects and assessment of alternative formulation performance" from ASCPT conference
Access here - "Using formulation design spaces and clinical data to optimize development of modified release (MR) dosage forms" from CRS conference
Access here - "An integrated radiolabelled study to determine the mass balance, metabolite profile and identification, and absolute bioavailability of nolasiban in healthy female subjects" from ISSX conference
Access here - “Novel copper protein speciation method for calculating serum non-ceruloplasmin copper: a comparative analysis” from EBF conference
Access here - “Analysis of ranitidine reference materials using a six n-nitrosamine LC-MS/MS assay” from EBF conference
Access here
Scientific Papers
- "Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772” in Pharmaceutical Research Journal
Access here - "Pharmacokinetics and Metabolism of Ziritaxestat (GLPG1690) in Healthy Male Volunteers Following Intravenous and Oral Administration" in Clinical Pharmacology in Drug Development journal
Access here - "Development and Approval of Rybelsus – Ushering in a New Era in Peptide Delivery" in Drug Delivery and Translational Research Journal
Access here - "Inductively coupled plasma mass spectrometry method for plasma and intracellular antimony quantification applied to pharmacokinetics of meglumine antimoniate" in Bioanalysis journal
Access here - "Dose Finding and Food Effect Studies of a Novel Abiraterone Acetate Formulation for Oral Suspension in Comparison to a Reference Formulation in Healthy Male Subjects." in MDPI
Access here